Cumberland Pharmaceuticals Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cumberland Pharmaceuticals Inc. (CPIX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $108.23 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.45M.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.35M.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $8.04M.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.29M, a 2.23% increase year-over-year.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $6.71M.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$991.36K.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$1.41M, a 109.67% decline from fiscal 2022.
- Cumberland Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $14.54M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $108.23K 10-Q · filed 2026-08-07 | $8.15M derived: sum of 3 quarters · filed 2026-08-07 | $9.44M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$1.35M 10-Q · filed 2026-05-08 | $6.70M derived: sum of 2 quarters · filed 2026-05-08 | $7.98M derived: sum of 3 quarters · filed 2026-05-08 | $5.96M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $9.33M derived: sum of 2 quarters · filed 2026-03-09 | $7.31M derived: sum of 3 quarters · filed 2026-08-07 | $6.71M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$734.66K derived: sum of 2 quarters · filed 2026-08-07 | -$1.33M 10-Q · filed 2025-11-07 | -$1.66M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$2.62M 10-Q · filed 2026-08-07 | -$2.02M 10-Q · filed 2025-08-08 | -$2.95M derived: sum of 3 quarters · filed 2026-08-07 | -$1.69M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$600.04K 10-Q · filed 2026-05-08 | -$924.34K derived: sum of 2 quarters · filed 2026-05-08 | $334.48K derived: sum of 3 quarters · filed 2026-05-08 | -$945.86K derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | -$324.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $934.53K derived: sum of 2 quarters · filed 2026-03-09 | -$345.82K derived: sum of 3 quarters · filed 2026-03-09 | -$991.36K 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$21.52K derived: sum of 2 quarters · filed 2025-11-07 | -$667.07K 10-Q · filed 2025-11-07 | -$3.98M derived: sum of 4 quarters · filed 2025-11-07 | ||
| 2024-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$1.93M 10-Q · filed 2025-08-08 | -$5.23M derived: sum of 3 quarters · filed 2025-08-08 | -$3.72M derived: sum of 4 quarters · filed 2025-08-08 | ||
| 2024-03-31 | -$645.54K 10-Q · filed 2025-05-09 | -$3.95M derived: sum of 2 quarters · filed 2025-05-09 | -$2.44M derived: sum of 3 quarters · filed 2025-05-09 | -$945.64K derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | -$3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$1.79M derived: sum of 2 quarters · filed 2025-03-07 | -$300.10K derived: sum of 3 quarters · filed 2025-03-07 | -$1.41M 10-K · filed 2025-03-07 | $3.72M 10-K · filed 2024-03-13 | |
| 2023-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $3.01M derived: sum of 2 quarters · filed 2024-11-08 | $1.90M 10-Q · filed 2024-11-08 | $7.66M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $386.61K 10-Q · filed 2024-08-09 | $534.54K 10-Q · filed 2023-08-11 | $6.14M derived: sum of 3 quarters · filed 2024-08-09 | $10.26M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$1.11M 10-Q · filed 2024-05-10 | $4.65M derived: sum of 2 quarters · filed 2024-05-10 | $8.77M derived: sum of 3 quarters · filed 2024-05-10 | $8.97M derived: sum of 4 quarters · filed 2024-05-10 | ||
| 2022-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $9.88M derived: sum of 2 quarters · filed 2024-03-13 | $10.07M derived: sum of 3 quarters · filed 2024-03-13 | $14.54M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $4.32M derived: sum of 2 quarters · filed 2023-11-13 | $8.78M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $197.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $4.66M 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | $4.46M 10-Q · filed 2023-05-12 | |||||
| 2021-12-31 | -$757.59K 10-K · filed 2023-03-13 | |||||
| 2020-12-31 | $6.57M 10-K · filed 2022-03-11 | |||||
| 2019-12-31 | $3.22M 10-K · filed 2022-03-11 | $1.82M 10-K · filed 2020-03-20 | ||||
| 2018-12-31 | $4.15M 10-K · filed 2021-03-12 | $4.31M 10-K · filed 2019-03-12 | ||||
| 2017-12-31 | $339.75K 8-K · filed 2020-12-10 | $2.31M 10-K · filed 2018-03-09 | ||||
| 2016-12-31 | $191.90K 10-K · filed 2019-03-12 | |||||
| 2015-12-31 | $1.48M 10-K · filed 2018-03-09 | |||||
| 2014-12-31 | $3.85M 10-K · filed 2017-03-13 | |||||
| 2013-12-31 | $58.85K 10-K · filed 2016-03-14 | |||||
| 2012-12-31 | $194.57K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $3.01M derived: sum of 2 quarters · filed 2015-03-09 | $4.66M derived: sum of 3 quarters · filed 2015-03-09 | $4.37M 10-K · filed 2015-03-09 | ||
| 2012-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $4.46M derived: sum of 2 quarters · filed 2012-11-02 | $4.18M 10-Q · filed 2012-11-02 | $2.56M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $1.36M 10-Q · filed 2012-08-09 | -$252.53K derived: sum of 3 quarters · filed 2014-03-11 | $1.65M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2012-03-31 | -$282.86K 10-Q · filed 2012-05-04 | -$1.90M derived: sum of 2 quarters · filed 2014-03-11 | $4.14K derived: sum of 3 quarters · filed 2014-03-11 | $2.04M derived: sum of 4 quarters · filed 2014-03-11 | ||
| 2011-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $287.01K derived: sum of 2 quarters · filed 2014-03-11 | $2.32M derived: sum of 3 quarters · filed 2014-03-11 | $2.30M 10-K · filed 2014-03-11 | ||
| 2011-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $3.94M derived: sum of 2 quarters · filed 2012-11-02 | $3.91M 10-Q · filed 2012-11-02 | $4.95M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-06-30 | $2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $2.01M 10-Q · filed 2012-08-09 | $3.05M derived: sum of 3 quarters · filed 2013-03-12 | $1.87M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-03-31 | -$23.99K 10-Q · filed 2012-05-04 | $1.02M derived: sum of 2 quarters · filed 2013-03-12 | -$160.26K derived: sum of 3 quarters · filed 2013-03-12 | |||
| 2010-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$136.27K derived: sum of 2 quarters · filed 2013-03-12 | $201.72K 10-K · filed 2013-03-12 | |||
| 2010-09-30 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$840.43K 10-Q · filed 2011-11-07 | ||||
| 2010-06-30 | $338.00K 10-Q · filed 2011-08-08 | |||||
| 2009-12-31 | $6.57M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |